# MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

> **NCT06911008** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 42 (estimated)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** SCD1 Inhibitor MTI-301

## Key facts

- **NCT ID:** NCT06911008
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2027-04-09
- **Final completion:** 2027-04-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911008, "MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06911008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*